FDA Issues Complete Response Letter for Reproxalap in Dry Eye Disease
- nuaxia
- 7月30日
- 読了時間: 1分
Aldeyra Therapeutics’ new drug application for reproxalap was not approved due to insufficient clinical trial data demonstrating efficacy.
The FDA issued a complete response letter for reproxalap, citing inconsistencies in the clinical trial results and insufficient evidence of its effectiveness for dry eye disease.
Aldeyra Therapeutics will request a Type A meeting with the agency to discuss potential pathways forward, while no additional trials are currently required.
Alert Type | Complete Response Letter (FDA) |
Drug/Device Name | Reproxalap |
Indication | Dry eye disease |
Therapy Area(s) | Ophthalmology |
Geography | US (FDA) |
What Changed | The FDA issued a complete response letter for Aldeyra Therapeutics’ NDA for reproxalap, citing insufficient evidence of efficacy and inconsistencies in clinical trial results under the proposed conditions of use. |
Clinical Relevance | Reproxalap’s effectiveness remains unproven; further guidance from the FDA will be required before potential market access. |
Source Link | |
Date | 27-Feb-2026 |
Status | Draft |
Notes | FDA recommended exploring reasons for trial failures and identifying responsive populations; no new trials required. Aldeyra plans a Type A meeting within 30 days. Company cash position as of 31-Dec-2025: $70m, supporting operations into 2028. |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
コメント